← Back to Search

Oxytocin Analog

Merotocin for Premature Birth (MERMAID Trial)

Phase 2
Waitlist Available
Research Sponsored by Ferring Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1 to 14

Summary

This trial looks at whether a drug can help women with preterm babies and low milk production to make more milk.

Eligible Conditions
  • Premature Birth
  • Low Milk Supply

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1 to 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 1 to 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Volume of Mother's Own Milk (MoM)
Secondary study objectives
Proportion of Participants With a Daily Volume of MoM ≥ 500 mL
Proportion of Participants With a Daily Volume of MoM ≥ 750 mL
Time to First Occurrence of Daily Volume of MoM ≥ 500 mL
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Merotocin (a selective oxytocin-receptor agonist)Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Ferring PharmaceuticalsLead Sponsor
321 Previous Clinical Trials
1,243,136 Total Patients Enrolled
1 Trials studying Premature Birth
163 Patients Enrolled for Premature Birth
Global Clinical ComplianceStudy DirectorFerring Pharmaceuticals
69 Previous Clinical Trials
1,159,453 Total Patients Enrolled
~1 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top